loading
前日終値:
$1.98
開ける:
$1.98
24時間の取引高:
91,712
Relative Volume:
0.09
時価総額:
$5.46M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.52%
1か月 パフォーマンス:
-66.49%
6か月 パフォーマンス:
-84.86%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$1.94
$2.0442
1週間の範囲:
Value
$1.90
$3.18
52週間の値動き範囲:
Value
$1.76
$1,095.00

Cero Therapeutics Holdings Inc Stock (CERO) Company Profile

Name
名前
Cero Therapeutics Holdings Inc
Name
セクター
Healthcare (1189)
Name
電話
650-407-2376
Name
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CERO's Discussions on Twitter

CERO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CERO
Cero Therapeutics Holdings Inc
1.94 5.46M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
486.70 125.43B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
706.55 76.60B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
666.85 39.57B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.51 35.33B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.54 28.08B 3.30B -501.07M 1.03B -2.1146

Cero Therapeutics Holdings Inc (CERO) 最新ニュース

pulisher
Jan 31, 2025

Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World

Jan 31, 2025
pulisher
Jan 29, 2025

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Down 97.9% in January - Defense World

Jan 29, 2025
pulisher
Jan 27, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 27, 2025
pulisher
Jan 21, 2025

CERO Therapeutics secures NASDAQ compliance extension - MSN

Jan 21, 2025
pulisher
Jan 14, 2025

CERO stock touches 52-week low at $2.83 amid steep annual decline - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 09, 2025

Phoenix Biotech Acquisition Corp. Appoints Brian Atwood as Chief Executive Officer - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics : Amendments to Bylaws Form 8 K - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Appoints Chris Ehrlich CEO - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Appoints Kristen Pierce as Chief Development Officer - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Jan 09, 2025
pulisher
Jan 09, 2025

CERo Therapeutics Holdings, Inc. Announces CEO Changes - Marketscreener.com

Jan 09, 2025
pulisher
Jan 08, 2025

CERo Therapeutics (NASDAQ:CERO) Hits New 12-Month LowTime to Sell? - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

CERo Therapeutics to implement reverse stock split - MSN

Jan 08, 2025
pulisher
Jan 07, 2025

Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn

Jan 07, 2025
pulisher
Jan 07, 2025

Cero Therapeutics to effect 1-for-100 reverse stock split - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - The Manila Times

Jan 06, 2025
pulisher
Jan 06, 2025

CERo Therapeutics Announces 1:100 Reverse Stock Split to Avoid Nasdaq Delisting - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

CERO stock plunges to 52-week low, touches $0.05 - Investing.com

Jan 06, 2025
pulisher
Jan 01, 2025

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - MSN

Jan 01, 2025
pulisher
Dec 30, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN

Dec 30, 2024
pulisher
Dec 18, 2024

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 18, 2024
pulisher
Dec 14, 2024

Cero Therapeutics holdings sees $400,456 in stock sales by YK Bioventures - Investing.com Australia

Dec 14, 2024
pulisher
Dec 11, 2024

Cero Therapeutics sees $383,369 in stock sales by YK Bioventures - Investing.com Australia

Dec 11, 2024
pulisher
Dec 07, 2024

CERo Therapeutics appoints Chris Ehrlich CEO - MSN

Dec 07, 2024
pulisher
Dec 06, 2024

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire

Dec 06, 2024
pulisher
Dec 06, 2024

CERo Therapeutics Names Chris Ehrlich Permanent CEO, Advances Novel Cancer Treatment Pipeline - StockTitan

Dec 06, 2024
pulisher
Nov 21, 2024

Cero therapeutics investor Sloan Stuart sells $55,538 in stock By Investing.com - Investing.com India

Nov 21, 2024
pulisher
Nov 20, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.70% - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

CERo Therapeutics Holdings Inc. (CERO) reports earnings - Quartzy

Nov 20, 2024
pulisher
Nov 16, 2024

Selling Your CERo Therapeutics Holdings Inc (CERO) Stock? Here’s What You Need To Know - Stocks Register

Nov 16, 2024
pulisher
Nov 15, 2024

Cero Therapeutics holdings sees $325,000 stock sale by YK Bioventures - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

FDA clears CERo's new AML drug for phase 1 trials - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

FDA clears CERo's new AML drug for phase 1 trials By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

CERo Therapeutics, Inc. Receives FDA Clearance of - GlobeNewswire

Nov 15, 2024
pulisher
Nov 15, 2024

CERo Therapeutics Secures FDA Clearance for Novel AML Treatment Clinical Trial | CERO Stock News - StockTitan

Nov 15, 2024
pulisher
Nov 15, 2024

Nasdaq Tumbles Over 200 Points; Alibaba Posts Upbeat SalesArena Group Holdings (AMEX:AREN) - Benzinga

Nov 15, 2024
pulisher
Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024
pulisher
Nov 13, 2024

Nuclear stock Oklo jumps on data center partnership - Investing.com

Nov 13, 2024
pulisher
Nov 12, 2024

U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn

Nov 12, 2024
pulisher
Nov 11, 2024

United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com

Nov 11, 2024
pulisher
Nov 11, 2024

CERo Therapeutics Holdings, Inc. (CERO): 173% Stock Surge Driven by Promising Preclinical Data for Lead Compound CER-1236 - BP Journal

Nov 11, 2024
pulisher
Nov 11, 2024

Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga

Nov 11, 2024

Cero Therapeutics Holdings Inc (CERO) 財務データ

Cero Therapeutics Holdings Inc (CERO) の財務データはありません。詳細については、他の銘柄を確認してください。

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$80.53
price down icon 0.72%
$21.41
price up icon 3.18%
$357.45
price up icon 1.14%
$5.35
price up icon 5.11%
biotechnology ONC
$228.49
price up icon 2.64%
$123.02
price up icon 5.06%
大文字化:     |  ボリューム (24 時間):